Form 4: Eledon Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Eledon Pharmaceuticals' President, Steven Perrin, was granted stock options for 243,000 shares and 27,000 restricted stock units on January 10, 2025.

Summary

• Steven Perrin, President of Eledon Pharmaceuticals, received stock options for 243,000 shares at an exercise price of $4.04 per share on January 10, 2025.
• These options vest over a period starting January 10, 2026, with 60,750 shares vesting initially, followed by 6.25% of the remaining shares vesting quarterly over three years, ending January 10, 2029.
• The vesting is contingent on continuous service and may accelerate under certain circumstances, such as termination or a change of control.
• Perrin also received 27,000 restricted stock units (RSUs), each representing one share of common stock, on January 10, 2025.
• The RSUs vest with 50% vesting on January 10, 2027, and the remaining 50% on January 10, 2028, also contingent on continuous service and subject to accelerated vesting under certain conditions.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The granting of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.
• The accelerated vesting provisions provide protection for the executive in the event of termination or a change of control.

Risks

• The vesting of the stock options and RSUs is contingent on the executive's continuous service, which could be a risk if the executive leaves the company.
• The accelerated vesting provisions could result in a significant number of shares being issued if certain events occur.

Industry Context

The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard forms of executive compensation in the biotechnology and pharmaceutical industries.
• Vesting schedules are typically structured to encourage long-term performance and retention, with vesting periods of 3-4 years being common.
• The specific terms of the grants, such as the exercise price and vesting schedule, are often tailored to the individual executive and the company's specific circumstances.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity compensation, executive compensation, vesting, Eledon Pharmaceuticals, Steven Perrin